News and Community

Antipsychotic Treatment, Bipolar I Disorder, Healthcare Technology, Long-acting Antipsychotics, Long-acting Injectable, Medincell, Olanzapine, Olanzapine Lai, Phase 3 Trial, Psychiatric Treatment, Real-world Evidence, Schizophrenia Care, Schizophrenia Treatment, Teva, Uzedy

September 21, 2026

Medincell Partner Teva Presents New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026

Alfasigma, Axial Spondyloarthritis, Axspa Treatment, Filgotinib, Healthcare Technology, Inflammatory Disease, Jak1 Inhibitor, Jyseleca, Olinguito, Phase 3 Trial, Rheumatology

September 21, 2026

Alfasigma’s Jyseleca (filgotinib) Receives Positive CHMP Recommendation for New Axial Spondyloarthritis Indication

Adjuvant Therapy, Astrazeneca, Daiichi Sankyo, Destiny-endometrial02, Endometrial Cancer, Enhertu, Future Of Oncology, Her2, Phase 3 Trial

December 22, 2025

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Started as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer